Skip to Content

Cellectar Biosciences Inc CLRB

Morningstar Rating
$3.29 −0.16 (4.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CLRB is trading at a 16% discount.
Price
$3.31
Fair Value
$4.60
Uncertainty
Extreme
1-Star Price
$88.33
5-Star Price
$3.92
Economic Moat
Qxk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLRB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.45
Day Range
$3.253.47
52-Week Range
$1.304.01
Bid/Ask
$3.29 / $3.30
Market Cap
$40.43 Mil
Volume/Avg
1.1 Mil / 1.5 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
15

Valuation

Metric
CLRB
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
CLRB

Financial Strength

Metric
CLRB
Quick Ratio
1.15
Current Ratio
1.22
Interest Coverage
Quick Ratio
CLRB

Profitability

Metric
CLRB
Return on Assets (Normalized)
−215.17%
Return on Equity (Normalized)
−1,213.30%
Return on Invested Capital (Normalized)
−749.24%
Return on Assets
CLRB
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQgh$544.0 Bil
VRTX
Vertex Pharmaceuticals IncDphhy$108.7 Bil
REGN
Regeneron Pharmaceuticals IncRrgtw$103.9 Bil
MRNA
Moderna IncCbkl$33.2 Bil
ARGX
argenx SE ADRWsxpn$23.4 Bil
BNTX
BioNTech SE ADRBjx$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncDwzjw$18.9 Bil
BMRN
Biomarin Pharmaceutical IncTxcknwj$16.7 Bil
RPRX
Royalty Pharma PLC Class ALzdgcgw$13.5 Bil
INCY
Incyte CorpRnrwph$13.2 Bil

Sponsor Center